This clinical trial is focused on studying the treatment of ovarian cancer that has returned after initial treatment. The treatment being tested is called Hyperthermic Intraperitoneal Chemotherapy (HIPEC), which involves delivering heated chemotherapy directly into the abdominal area. The specific medication used in this treatment is cisplatin, which is administered as a solution for injection. The purpose of the study is to see if this approach can improve the survival of patients with ovarian cancer relapse compared to those who do not receive HIPEC.
Participants in the study will be randomly assigned to one of two groups. One group will receive the HIPEC treatment with cisplatin, while the other group will not receive HIPEC. The study will monitor the participants over a period to assess their overall survival and any side effects they may experience. The study will also look at other factors such as the time until the cancer returns, the quality of life of the participants, and any pain they may experience.
Throughout the study, various assessments will be conducted to gather information on the effectiveness and safety of the treatment. This includes monitoring for any complications or side effects, particularly focusing on kidney health, as well as evaluating the participants’ quality of life and pain levels. The study aims to provide valuable insights into whether HIPEC with cisplatin can be a beneficial treatment option for patients with recurrent ovarian cancer.
France 
